prescription glp-1 medications Since 2020, the number of prescriptions for drugs—such as Ozempic, Wegovy, or Mounjaro—has more than tripled. But research about their use and side effects is still taking shape. We asked a Are GLP-1 drugs for everyone?

CJC-1295 + Ipamorelin Regulatory Status As of June 2026, neither CJC-1295 nor Ipamorelin is FDA-approved for any clinical use

J., Hughes, C

Given its involvement in cross-talk between signaling pathways, GILZs immune-regulatory mechanism may extend beyond its currently known functions, highlighting its potential as a focal point for future research

In the STEP 1 trial: Participants who took the medication lost an average of 14.9% of their body weight over 68 weeks By comparison, those who received a placebo lost only 2.4% Nearly 86% of GLP-1 users lost at least 5% of their body weight, an important clinical marker Additional real-world data backs this up